Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

Area of Science:

• Neuro-oncology
• Pharmacology
• Immunotherapy

Background:

• Central nervous system (CNS) lymphomas are typically CD20-positive B-cell neoplasms.
• Intravenous rituximab achieves low cerebrospinal fluid (CSF) levels (0.1% of serum), limiting its efficacy for CNS disease.
• Lymphomatous meningitis is a common complication of non-Hodgkin lymphoma.

Purpose of the Study:

• To evaluate the safety and pharmacokinetics of direct intrathecal rituximab administration.
• To determine the feasibility of intrathecal rituximab for CNS lymphoma treatment.

Main Methods:

• Cynomolgus monkeys received direct intrathecal administration of rituximab.
• Safety was assessed through observation for acute and delayed toxicity, including neurological effects.
• Pharmacokinetics were analyzed by measuring drug clearance from CSF.

Main Results:

• No significant acute or delayed toxicity, including neurological adverse events, was observed.
• CSF drug clearance exhibited biphasic kinetics.
• The terminal half-life of rituximab in CSF was determined to be 4.96 hours.

Conclusions:

• Direct intrathecal administration of rituximab appears safe in a non-human primate model.
• The pharmacokinetic profile supports further investigation in human clinical trials.
• These findings provide a basis for a Phase 1 study of intrathecal rituximab in patients with recurrent lymphomatous meningitis.